Industry

Digital, software and AI for pharmaceuticals and life sciences

Where data integrity is a regulatory obligation, promotion to the public is largely prohibited, and every system that touches quality must be validated.

Discuss your situation All services

Life sciences is the sector where the constraints bind hardest and earliest. Systems touching manufacturing, quality or clinical data fall under GxP expectations, which means validation, audit trail and data integrity are requirements rather than qualities — and a system that cannot evidence what happened is not usable regardless of what it does.

The commercial side is equally constrained. Advertising prescription medicines to the public is prohibited in the European Union, which removes most of what marketing normally means and pushes the work toward professional audiences, disease awareness and corporate communication.

Why this sector is moving now

Data integrity expectations have hardened. Regulators examine whether records are attributable, legible, contemporaneous, original and accurate, and increasingly whether the systems producing them enforce that rather than rely on procedure.

Supply chain traceability is now serialised for medicinal products in the EU, with verification at dispensing. That has pushed traceability from a documentation exercise into a real-time systems obligation with external interfaces.

The commercial model has shifted toward specialist and smaller-population products, which changes marketing from broad awareness to precise identification of a small number of prescribers and centres — a data problem rather than a media one.

The pressures behind it

GxP validation: Systems touching quality or clinical data requiring validation and audit trail before use.
Data integrity expectations: Records that must be attributable and contemporaneous, enforced by the system rather than by procedure.
Promotional restrictions: Prescription medicine advertising to the public prohibited across the EU.
Serialisation and verification: Traceability obligations with real-time external interfaces rather than internal records.
Document control: Controlled documents with versioning, approval and retention requirements measured in decades.
Specialist audiences: Small, precisely identified prescriber populations rather than broad markets.

Where the work usually starts

The systems and channels a pharmaceutical and life sciences companies typically needs joined up. Most engagements begin at one spoke and widen only if it earns it.

Usually document and quality record consolidation outside the validated estate — the reporting, analytics and administrative layer around GxP systems rather than inside them. That is where effort is genuinely recoverable without triggering revalidation.

Medical information and professional-facing content follows. We do not touch validated systems themselves; that is specialist work with a specialist supply chain, and we say so rather than take it.

Marketing and brand for pharmaceutical and life sciences companies

Brand Strategy & Development: Corporate positioning rather than product, since product claims are tightly controlled. What differentiates a mid-sized pharma or CDMO commercially is usually capability, therapeutic focus or reliability of supply, and those are claims that survive review.
Brand Management: Every promotional and non-promotional piece typically requires medical, legal and regulatory review with a retained approval record. Brand management here is inseparable from that workflow, and templates that pre-satisfy review save more time than any style guide.
Social Media Strategy: Corporate and recruitment focused, with disease awareness where permitted and carefully separated from product promotion. Adverse event reporting obligations attach to anything a patient says publicly, which is a genuine operational consideration.
Social Media Management: Pharmacovigilance is the constraint most agencies miss: a comment describing a side effect creates a reporting obligation with a deadline. Monitoring and escalation processes have to exist before an account does.
Content Creation & Creative Production: Professional and corporate content produced inside a review workflow. Timelines have to accommodate review cycles honestly, because a production schedule that assumes approval is instant will slip on every asset.
Digital Marketing: Audience precision replaces reach. Identifying and reaching a specific prescriber population or treatment centre is a targeting and data exercise, and broad digital metrics describe almost nothing useful.
Paid Advertising: Prescription product advertising to the public is prohibited in the EU, which leaves professional targeting through restricted channels, corporate and recruitment advertising, and permitted disease awareness. The constraints are the strategy rather than a limitation on it.
Search Engine Optimisation: Corporate, capability and recruitment content, plus disease awareness within permitted boundaries. Medical accuracy and review are the quality bar, and unreviewed health content is a genuine liability.
Email, SMS & WhatsApp Marketing: Professional communications to healthcare audiences with consent handled under both marketing and professional codes. Not a consumer channel in this sector.
Lead Generation & Prospecting: Applicable in B2B life sciences — CDMO, equipment, services — where the customer is another company. Not applicable to prescriber or patient identification, which is governed by entirely different rules.

IT, software and AI for pharmaceutical and life sciences companies

Website Design & Development: Frequently multiple sites with different audiences and different regulatory positions: corporate, professional, patient information. Geo-gating and audience declaration are common requirements rather than unusual ones.
CRM & Sales Systems: Field force systems and medical affairs interactions carry transparency reporting obligations in many markets, meaning interactions with healthcare professionals must be recorded and in some cases disclosed publicly.
Business Process Automation: Outside the validated estate: reporting assembly, document routing for review, training compliance tracking and supplier qualification. Inside it, change is validated and slow for good reason.
AI Automation Systems: Document classification and extraction in the administrative layer, and literature screening support with human review. Anything affecting product quality, safety assessment or a regulatory submission is validated territory and out of scope for us.
AI Knowledge Bases & RAG: Standard operating procedures, regulatory guidance, submission history and technical documentation, retrievable with citations. In a sector where the answer must be traceable to a controlled document, source referencing is the entire requirement.
AI Voice & Customer Communication: Very limited. Medical information lines carry pharmacovigilance obligations that make automated handling inappropriate for anything beyond routing.
Custom Software & Platforms: Justified in the non-validated layer: portals, reporting tools, supplier interfaces. Validated system development is a specialist discipline with its own supply chain and we would point you to it.
Data Engineering & BI: Reporting across manufacturing, quality and supply data with lineage documented, because a figure in this sector has to be traceable to its source record. That requirement shapes the architecture more than volume does.
Cloud, DevOps & Infrastructure: Validation, qualification and change control apply to infrastructure supporting GxP systems. Where we work is generally alongside rather than inside that estate, and being clear about the boundary is part of the engagement.
Systems Integration: Quality to document control, serialisation to supply systems, ERP to reporting. Audit trail and data integrity are the properties that matter; an integration that transforms data without an auditable record is not acceptable here.
Digital Transformation Consulting: The audit usually finds substantial recoverable effort in the administrative layer around validated systems, which is where change is possible without revalidation and where nobody has looked.
Maintenance & Ongoing Support: Regulatory change and periodic review are continuous. For any AI in the administrative layer, scheduled re-evaluation matters because unmeasured drift in a regulated organisation is a finding waiting to happen.

What is specific to this sector

GxP data integrity expectations require records to be attributable, legible, contemporaneous, original and accurate, and regulators increasingly expect systems to enforce this rather than procedures to compensate for systems that do not. Any system in scope requires validation, and changes to it require assessment — which is why the recoverable effort is usually in the non-validated layer around it.

Advertising prescription-only medicines to the general public is prohibited across the European Union, and the boundary between disease awareness and product promotion is narrower than most marketers assume. Content in this space should be reviewed by regulatory affairs before publication rather than after.

Pharmacovigilance obligations mean that an adverse event mentioned anywhere the company controls or monitors — including social media comments — creates a reporting obligation with a regulatory deadline. Any social presence therefore needs a monitoring and escalation process in place before it is opened.

The Falsified Medicines Directive requires unique identifiers and anti-tampering devices on prescription medicine packs, verified through a European and national repository system at dispensing. Serialisation data therefore flows outward to shared infrastructure, and mismatches surface at the pharmacy counter rather than inside the manufacturer's quality system.

Pharmacovigilance obligations mean an adverse event may arrive through any channel — a call, an email, a social media comment, a market research response — and must be captured and processed within defined timelines. Any customer-facing digital channel is therefore a potential intake point and needs a documented route into the safety system before it goes live.

Not legal or regulatory advice. Sector rules described here are scoping context, current to our latest review. Confirm what applies to your business with a qualified adviser.

Questions

Do you work inside validated systems?

No. Validated GxP system development is a specialist discipline with its own supply chain, and we would point you to it rather than take the work. We work in the administrative and reporting layer around that estate, which is where change is possible without revalidation.

What can we actually advertise?

Not prescription products to the public within the EU. Professional audiences through restricted channels, corporate and recruitment communication, and disease awareness within permitted boundaries. The constraints shape the strategy rather than limit an otherwise normal one.

What is the pharmacovigilance issue with social media?

A comment describing a side effect on a channel you control creates a reporting obligation with a deadline. That means monitoring and escalation must exist before an account is opened, not after an incident.

Where is recoverable effort in a regulated organisation?

Almost always in the administrative layer: reporting assembly, document routing, training compliance, supplier qualification. It is unglamorous, it is outside the validated estate, and nobody has usually looked at it.

Can AI read our documents?

In the non-validated layer with human review, yes — retrieval with citations is genuinely valuable where every answer must trace to a controlled document. Anything influencing a quality or safety decision is validated territory.

How do review cycles affect timelines?

Substantially, and a production plan that assumes instant approval will slip on every asset. We build review into the schedule rather than discovering it, which is one of the more common failures of agencies new to this sector.

What does it cost?

Quoted per phase after a discovery call, with the review and documentation overhead scoped explicitly rather than absorbed.

Can we run social media accounts safely?

Only with monitoring and a documented route into pharmacovigilance, because an adverse event mentioned in a comment triggers obligations with deadlines. The channel is workable; opening it without that route is what creates the exposure.

Where does serialisation data go wrong?

Usually at the interface with the repository system, where a mismatch appears at the point of dispensing rather than inside the quality system. Monitoring that outward flow, rather than assuming successful submission, is what catches it early.